A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

Detalles Bibliográficos
Autores principales: Long, Georgina V, Dummer, Reinhard, Ribas, Antoni, Puzanov, Igor, Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert HI, Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J, Gajewski, Thomas F, Kirkwood, John M, Kuznetsova, Olga, Chen, Lisa, Kaufman, David R, Chou, Jeffrey, Hodi, F Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645515/
http://dx.doi.org/10.1186/2051-1426-3-S2-P181
_version_ 1782400830022877184
author Long, Georgina V
Dummer, Reinhard
Ribas, Antoni
Puzanov, Igor
Michielin, Olivier
VanderWalde, Ari
Andtbacka, Robert HI
Cebon, Jonathan
Fernandez, Eugenio
Malvehy, Josep
Olszanski, Anthony J
Gajewski, Thomas F
Kirkwood, John M
Kuznetsova, Olga
Chen, Lisa
Kaufman, David R
Chou, Jeffrey
Hodi, F Stephen
author_facet Long, Georgina V
Dummer, Reinhard
Ribas, Antoni
Puzanov, Igor
Michielin, Olivier
VanderWalde, Ari
Andtbacka, Robert HI
Cebon, Jonathan
Fernandez, Eugenio
Malvehy, Josep
Olszanski, Anthony J
Gajewski, Thomas F
Kirkwood, John M
Kuznetsova, Olga
Chen, Lisa
Kaufman, David R
Chou, Jeffrey
Hodi, F Stephen
author_sort Long, Georgina V
collection PubMed
description
format Online
Article
Text
id pubmed-4645515
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46455152015-11-20 A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) Long, Georgina V Dummer, Reinhard Ribas, Antoni Puzanov, Igor Michielin, Olivier VanderWalde, Ari Andtbacka, Robert HI Cebon, Jonathan Fernandez, Eugenio Malvehy, Josep Olszanski, Anthony J Gajewski, Thomas F Kirkwood, John M Kuznetsova, Olga Chen, Lisa Kaufman, David R Chou, Jeffrey Hodi, F Stephen J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645515/ http://dx.doi.org/10.1186/2051-1426-3-S2-P181 Text en Copyright © 2015 Long et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Long, Georgina V
Dummer, Reinhard
Ribas, Antoni
Puzanov, Igor
Michielin, Olivier
VanderWalde, Ari
Andtbacka, Robert HI
Cebon, Jonathan
Fernandez, Eugenio
Malvehy, Josep
Olszanski, Anthony J
Gajewski, Thomas F
Kirkwood, John M
Kuznetsova, Olga
Chen, Lisa
Kaufman, David R
Chou, Jeffrey
Hodi, F Stephen
A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title_full A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title_fullStr A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title_full_unstemmed A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title_short A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
title_sort phase i/iii, multicenter, open-label trial of talimogene laherparepvec (t-vec) in combination with pembrolizumab for the treatment of unresected, stage iiib-iv melanoma (masterkey-265)
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645515/
http://dx.doi.org/10.1186/2051-1426-3-S2-P181
work_keys_str_mv AT longgeorginav aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT dummerreinhard aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT ribasantoni aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT puzanovigor aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT michielinolivier aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT vanderwaldeari aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT andtbackaroberthi aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT cebonjonathan aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT fernandezeugenio aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT malvehyjosep aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT olszanskianthonyj aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT gajewskithomasf aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kirkwoodjohnm aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kuznetsovaolga aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT chenlisa aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kaufmandavidr aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT choujeffrey aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT hodifstephen aphaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT longgeorginav phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT dummerreinhard phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT ribasantoni phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT puzanovigor phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT michielinolivier phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT vanderwaldeari phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT andtbackaroberthi phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT cebonjonathan phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT fernandezeugenio phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT malvehyjosep phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT olszanskianthonyj phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT gajewskithomasf phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kirkwoodjohnm phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kuznetsovaolga phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT chenlisa phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT kaufmandavidr phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT choujeffrey phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265
AT hodifstephen phaseiiiimulticenteropenlabeltrialoftalimogenelaherparepvectvecincombinationwithpembrolizumabforthetreatmentofunresectedstageiiibivmelanomamasterkey265

Ejemplares similares